Evidence map›Paper›PMID 40635067›Full record

ReviewEuropean journal of medical research2025

Research advances of matrix metalloproteinases family in uveal melanoma.

Yuning Chen, Yunyu Yan, Wenbin Wei

Abstract readReview
In one paragraph

Review in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yuning Chen *Beijing Tongren Eye Center, Beijing key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology & Visual Sciences Key Lab, Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Key Laboratory of Intelligent Diagnosis, Treatment and Prevention of Blinding Eye Diseases, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China.
Yunyu Yan *CT Room, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050051, People's Republic of China.
Wenbin WeiBeijing Tongren Eye Center, Beijing key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology & Visual Sciences Key Lab, Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Key Laboratory of Intelligent Diagnosis, Treatment and Prevention of Blinding Eye Diseases, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China. weiwenbintr@163.com.

Funding

Beijing Municipal Health Commission 2020-1-2052Beijing Science and Technology Planning Project Z201100005520045National Natural Science Foundation of China 82220108017Sanming Project of Medicine in Shenzen Municipality SZSM202311018
6 · The paper itself

Abstract

As a zinc-containing family of endopeptidases, matrix metalloproteinases (MMPs) are not only the main hydrolytic enzymes for the degradation of extracellular matrix and basement membrane, but also the main protein family involved in tumor metastasis. In addition to playing a key role in normal physiological processes, previous studies have shown that MMPs are also important in tumorigenesis and development, including but not limited to promoting epithelial-mesenchymal transformation, angiogenesis, and inducing the expression of adhesion molecules. Therefore, as a potential diagnostic marker and therapeutic target, the relationship between MMPs and carcinogenesis and metastasis has also been widely studied. As the most frequent intraocular malignant tumor in adults, uveal melanoma (UM) poses a great threat to patients' visual acuity and lives. MMPs contribute to UM progression by promoting extracellular matrix degradation, tumor microenvironment remodeling, and metastasis. Clinical and bioinformatic studies have identified MMPs as both prognostic biomarkers and potential therapeutic targets in UM, supported by their association with tumor characteristics, immune-related phenotypes, and the expression of endogenous inhibitors like TIMPs. This article comprehensively reviews the expression profiles and clinical significance of MMPs in UM, highlighting their roles in tumor progression, metastasis, and potential as therapeutic targets.

Indexed as

Matrix MetalloproteinasesMelanomaUveal NeoplasmsBiomarkers, TumorHumansTumor MicroenvironmentUveal MelanomaBiomarkers, TumorMatrix MetalloproteinasesExtracellular matrixMatrix metalloproteinasesTumor mircoenvironmentUveal melanoma

Identifiers

PMID40635067
PMCPMC12239450

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.